Inhibition of HIF-1α by Atorvastatin During ¹³¹I-RTX Therapy in Burkitt's Lymphoma Model.

ABSTRACT:

Backgrounds

Radioimmunotherapy (RIT) serves as a targeted therapy for non-Hodgkin lymphomas (NHL). Although HIF(Hypoxia-inducible factors)-1α is an important biomarker during radiation therapy, its role in NHL is unclear. Atorvastatin (ATV) is used as a combination drug for chemotherapy.

Methods

We investigated whether ATV downregulated tumor radio-resistance and enhanced the anticancer effect of ¹³¹I-RTX (rituximab) in Raji xenograft mouse models. First, the increased uptake and enhanced therapeutic effect of ¹³¹I-RTX by ATV was confirmed using molecular imaging in Raji xenograft subcutaneous model and orthotropic model with SPECT and IVIS images. Second, we examined the profile of differentially expressed miRNAs using miRNA array.

Results

We fo

SUBMITTER: Kim EH 

PROVIDER: S-EPMC7281655 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature